We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

A new liquid biopsy detects minimal residual disease and predicts early NSCLC recurrence months before imaging. More...
21 Oct 2026
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

A new two-step blood-testing strategy clarifies gray-zone p-Tau217, improves brain amyloid detection and reduces PET imaging. More...
21 Oct 2026
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Revvity has launched Signals LabGistics, an AI-first scientific workflow orchestration solution from its Revvity Signals Software business. More...
21 Oct 2026
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

An antibody-profiling approach detects inflammatory bowel disease signatures up to 10 years before diagnosis. More...
21 Oct 2026
Image: Biodesix is developing a radiomics-based lung nodule risk assessment test to complement its Nodify Lung portfolio (Photo courtesy of Biodesix)

Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment

A new AI-enabled multimodal test combines blood and CT radiomics to improve lung nodule risk assessment. More...
21 Oct 2026
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

An AI system automates QC, tumor detection, mitotic counts, and cellularity to speed pathology and cut failed molecular tests More...
21 Oct 2026
Image

GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026

GeneDx is presenting 27 scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting. More...
21 Oct 2026
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Copyright © 2000-2026 Globetech Media. All rights reserved.